Photo: Coolcaesar / Wikimedia Commons, CC BY-SA 4.0, cropped
A Jury Said Arm Broke Its Deal With Qualcomm and Awarded $2. Why the Real Fight Is Just Starting
- A federal jury in Wilmington, Delaware delivered a mixed verdict on October 13, 2026.
- For Qualcomm: Arm breached its architecture license by withholding technical information, and interfered with Qualcomm's relationship with Meta.
- Damages: $2 in total, $1 for each of those two claims.
- For Arm: the jury rejected Qualcomm's claims under the license's 'previous best deal' terms and found for Arm on four claims in all.
- Judge Maryellen Noreika now rules on contractual remedies. Arm shares fell about 1%; Qualcomm rose about 1%.
What happened
A federal jury in Wilmington, Delaware, returned its verdict on Tuesday, October 13, in the second trial between two of the most important companies in chips.
Arm designs the blueprints, called architectures, that most smartphone and many laptop chips are built on. It licenses them and collects royalties. Qualcomm is one of its biggest customers. It uses Arm's architecture to design the Snapdragon chips in Android phones and Windows laptops.
The scorecard
| Claim | Winner | Damages |
|---|---|---|
| Arm breached the architecture license by withholding technical information | Qualcomm | $1 |
| Arm interfered with Qualcomm's business with Meta | Qualcomm | $1 |
| Arm violated "previous best deal" terms (offering terms within 10% of its best deal) | Arm | — |
| Support, maintenance and other licensing claims | Arm | — |
Sources: CNBC, Tirias Research, October 13, 2026.
So Qualcomm won the claims that make headlines. Arm won more claims overall, and the damages were $2.
Why $2 isn't the real number
The tiny award was by design. Qualcomm's lawyer asked the jury for at least $1. Qualcomm didn't need a big check from the jury. It needed a finding that Arm broke the contract.
That finding sets up the next stage. Judge Maryellen Noreika will now rule on contractual remedies and Arm's licensing obligations, including issues around Arm's next-generation licensing terms. One report says those remedies could include suspending Qualcomm's royalty payments to Arm for a period. That's where real money could change hands.
How the market reacted
Both stocks barely moved: Arm fell about 1% and Qualcomm rose about 1%. Investors are waiting for the judge.
Why investors care
For Arm, royalties are the business. It collects a small fee on billions of chips a year. Qualcomm is one of its largest sources of royalties, so any ruling that lowers or pauses them would hit revenue directly.
For Qualcomm, the goal is freedom. It wants to design its own custom processors on Arm's architecture without Arm controlling the terms. That matters as it pushes into PCs and AI devices, where it competes with Apple, Intel, AMD and now Nvidia's own Arm-based laptop chip.
The Meta angle matters, too. The jury found Arm interfered with Qualcomm's relationship with Meta. Big tech companies are designing their own chips for AI, and both Arm and Qualcomm want that business.
How we got here
- 2022: Arm sued Qualcomm after Qualcomm bought chip startup Nuvia, arguing Nuvia's Arm license didn't transfer.
- 2024: A jury largely sided with Qualcomm. The court later entered judgment for Qualcomm. Arm has appealed.
- 2026: Qualcomm's own claims against Arm went to trial, leading to Tuesday's verdict.
What it means for you
Lawsuits are a real risk for single stocks. A company whose business depends on a few big customers can see its revenue reshaped by one court ruling. Our stock-picking checklist includes checking customer concentration and legal risk.
Index investors are covered either way. If you own a broad tech or semiconductor fund, you likely own both companies. Whatever one loses, the other may gain.
What to watch next
- Judge Noreika's ruling on remedies.
- Appeals. Arm's appeal of the Nuvia case is pending, and either side may appeal this one.
- Arm's next earnings report, for any comment on Qualcomm royalties.
Frequently asked questions
Who won the Arm vs Qualcomm trial in October 2026?
Both sides won something. On October 13, 2026 a Delaware jury found Arm breached its architecture license with Qualcomm and interfered with Qualcomm's relationship with Meta, but awarded only $2 in damages. The jury rejected Qualcomm's claims under the license's previous-best-deal terms and sided with Arm on four claims.
Why did the jury award Qualcomm only $2?
Qualcomm's lawyers asked the jury for at least $1 per claim, because the bigger prize is the contractual remedies a judge will decide. A nominal award establishes that Arm broke the agreement, which supports Qualcomm's case for those remedies.
What happens next in Arm vs Qualcomm?
Judge Maryellen Noreika will rule on contractual remedies and Arm's licensing obligations, including issues tied to its next architecture licensing terms. One report says the remedies could include suspending royalty payments for a period. Either side may also appeal.
How does the Qualcomm lawsuit affect Arm stock?
Arm earns money by licensing its chip designs and collecting royalties on every chip sold. Qualcomm is one of its largest customers. A ruling that lowers or pauses Qualcomm's royalties would cut Arm's revenue, while a narrow ruling would leave the business largely untouched. Arm shares fell about 1% after the verdict.
What is the history of the Arm and Qualcomm dispute?
Arm sued Qualcomm in 2022 after Qualcomm bought chip designer Nuvia, arguing Nuvia's license did not transfer. A 2024 jury largely sided with Qualcomm and the court later entered judgment in Qualcomm's favor; Arm has appealed. Qualcomm then brought its own claims, which led to this second trial.
Primary sources
- CNBC — Delaware jury awards Qualcomm $2 in damages, finds Arm breached license agreement (Oct. 13, 2026)
- Tirias Research — Qualcomm and Arm both claim victory in jury verdict
- Yahoo Finance / Stocktwits — Delaware jury delivers verdict in Qualcomm-Arm licensing battle
- Tom's Hardware — Qualcomm wins architecture breach verdict against Arm but gets just $2
- Arm Holdings — Form 20-F, fiscal 2026 (SEC)
Data & disclaimer: This article is for educational purposes only and is not financial or investment advice. Figures reflect data available as of Oct 14, 2026, and conditions change — always confirm current pricing, rates and rules with the provider before you act. Written by Elizabeta Dimoska. See our editorial standards and disclosure.
Comments